EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma

Ana Portelinha iD, Shenqiu Wang iD, Sara Parsa iD, Man Jiang iD, Alexander N Gorelick iD, Sagarajit Mohanty iD, Soumya Sharma iD, Elisa de Stanchina iD, Marjan Berishaj iD, Chunying Zhao iD, James Heward iD, Neeraj K Aryal iD und 7 weitere

Journal of Experimental Medicine · 2024

DOI: 10.1084/jem.20231143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2024. Verfasst von Ana Portelinha und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center , New York, NY, USA. Hauptthemen laut MEDLINE: Apoptosis, Histone-Lysine N-Methyltransferase, Mutation, Proto-Oncogene Proteins c-bcl-2. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: Follicular Lymphoma Foundation, Lymphoma Research Foundation, Leukemia and Lymphoma Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The translocation t(14;18) activates BCL2 and is considered the initiating genetic lesion in most follicular lymphomas (FL). Surprisingly, FL patients fail to respond to the BCL2 inhibitor, Venetoclax. We show that mutations and deletions affecting the histone lysine methyltransferase SETD1B (KMT2G) occur in 7% of FLs and 16% of diffuse large B cell lymphomas (DLBCL). Deficiency in SETD1B confers striking resistance to Venetoclax and an experimental MCL-1 inhibitor. SETD1B also acts as a tumor suppressor and cooperates with the loss of KMT2D in lymphoma development in vivo. Consistently, loss of SETD1B in human lymphomas typically coincides with loss of KMT2D. Mechanistically, SETD1B is required for the expression of several proapoptotic BCL2 family proteins. Conversely, inhibitors of the KDM5 histone H3K4 demethylases restore BIM and BIK expression and synergize with Venetoclax in SETD1B-deficient lymphomas. These results establish SETD1B as an epigenetic regulator of cell death and reveal a pharmacological strategy to augment Venetoclax sensitivity in lymphoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApoptosisHistone-Lysine N-MethyltransferaseMutationProto-Oncogene Proteins c-bcl-2AnimalsHumansMiceBridged Bicyclo Compounds, HeterocyclicCell Line, TumorDNA-Binding ProteinsDrug Resistance, NeoplasmLymphoma, B-CellLymphoma, Large B-Cell, DiffuseNeoplasm ProteinsSulfonamides

Substanzen

BCL2 protein, humanBridged Bicyclo Compounds, HeterocyclicDNA-Binding ProteinsHistone-Lysine N-MethyltransferaseKMT2D protein, humanNeoplasm ProteinsProto-Oncogene Proteins c-bcl-2SulfonamidesvenetoclaxSETD1B protein, human

Autor:innen und Institutionen

  • Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center , New York, NY, USA.
  • Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center , New York, NY, USA.
  • Department of Genetics, Harvard Medical School, Boston, MA, USA.
  • Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
  • Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center , New York, NY, USA.
  • Nucleome Therapeutics , Oxford, UK.

ORCID-Profile: Ana Portelinha, Shenqiu Wang, Sara Parsa, Man Jiang, Alexander N Gorelick, Sagarajit Mohanty, Soumya Sharma, Elisa de Stanchina, Marjan Berishaj, Chunying Zhao, James Heward, Neeraj K Aryal, Omid Tavana, Jiayu Wen, Jude Fitzgibbon, Ahmet Dogan, Anas Younes, Ari M Melnick, Hans-Guido Wendel

Förderung

  • Follicular Lymphoma Foundation
  • Lymphoma Research Foundation
  • Leukemia and Lymphoma Society
  • NCI NIH HHS
  • Geoffrey Beene Cancer Research Center
  • NIH HHS
  • Starr Cancer Consortium
  • Astrazeneca

Zitieren

APA

Portelinha, A., Wang, S., Parsa, S., Jiang, M., Gorelick, A. N., Mohanty, S., Sharma, S., de Stanchina, E., Berishaj, M., Zhao, C., Heward, J., Aryal, N. K., Tavana, O., Wen, J., Fitzgibbon, J., Dogan, A., Younes, A., Melnick, A. M., & Wendel, H. G. (2024). SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20231143

Vancouver

Portelinha A, Wang S, Parsa S, Jiang M, Gorelick AN, Mohanty S, et al. SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma. Journal of Experimental Medicine. 2024. doi:10.1084/jem.20231143

BibTeX
@article{Portelinha2024,
  author = {Portelinha, Ana and Wang, Shenqiu and Parsa, Sara and Jiang, Man and Gorelick, Alexander N and Mohanty, Sagarajit and Sharma, Soumya and de Stanchina, Elisa and Berishaj, Marjan and Zhao, Chunying and Heward, James and Aryal, Neeraj K and Tavana, Omid and Wen, Jiayu and Fitzgibbon, Jude and Dogan, Ahmet and Younes, Anas and Melnick, Ari M and Wendel, Hans-Guido},
  title = {SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma},
  journal = {Journal of Experimental Medicine},
  year = {2024},
  doi = {10.1084/jem.20231143}
}
Kostenlos starten →